Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2018 1
2019 3
2020 5
2021 15
2022 11
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
The On- and Off-Ramps of Oncology Accelerated Approval.
Fashoyin-Aje LA, Mehta GU, Beaver JA, Pazdur R. Fashoyin-Aje LA, et al. N Engl J Med. 2022 Oct 20;387(16):1439-1442. doi: 10.1056/NEJMp2208954. Epub 2022 Sep 21. N Engl J Med. 2022. PMID: 36129992 No abstract available.
To Adjudicate or Not Adjudicate: That Is the Question.
Hicks KA, Fashoyin-Aje LA, Amiri-Kordestani L. Hicks KA, et al. Among authors: fashoyin aje la. JACC CardioOncol. 2022 Dec 20;4(5):657-659. doi: 10.1016/j.jaccao.2022.11.003. eCollection 2022 Dec. JACC CardioOncol. 2022. PMID: 36636434 Free PMC article.
Making cancer research more inclusive.
Carpten JD, Fashoyin-Aje L, Garraway LA, Winn R. Carpten JD, et al. Among authors: fashoyin aje l. Nat Rev Cancer. 2021 Oct;21(10):613-618. doi: 10.1038/s41568-021-00369-7. Epub 2021 Jun 29. Nat Rev Cancer. 2021. PMID: 34188191 No abstract available.
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.
Amatya AK, Fiero MH, Bloomquist EW, Sinha AK, Lemery SJ, Singh H, Ibrahim A, Donoghue M, Fashoyin-Aje LA, de Claro RA, Gormley NJ, Amiri-Kordestani L, Sridhara R, Theoret MR, Kluetz PG, Pazdur R, Beaver JA, Tang S. Amatya AK, et al. Among authors: fashoyin aje la. Clin Cancer Res. 2021 Nov 1;27(21):5753-5756. doi: 10.1158/1078-0432.CCR-20-4912. Epub 2021 Jun 11. Clin Cancer Res. 2021. PMID: 34117032 Free PMC article. Review.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Donaldson JM, Seddiq M, Fusco MJ, Singla S, Pamuk GE, Lee-Alonso RJ, Mixter BD, Goldberg KB, Amiri-Kordestani L, de Claro RA, Drezner N, Gormley NJ, Kanapuru B, Lemery SJ, Fashoyin-Aje LA, Richardson NC, Singh H, Suzman DL, Theoret MR, Kluetz PG, Pazdur R. Donaldson JM, et al. Among authors: fashoyin aje la. Cancer Discov. 2023 Dec 12;13(12):2515-2524. doi: 10.1158/2159-8290.CD-23-1226. Cancer Discov. 2023. PMID: 38084090
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, Chow ECY, Xiong Y, Zirklelbach JF, Liu J, Charlab R, Pierce WF, Fesenko N, Beaver JA, Pazdur R, Kluetz PG, Lemery SJ. Casak SJ, et al. Among authors: fashoyin aje la. Clin Cancer Res. 2022 Jul 1;28(13):2733-2737. doi: 10.1158/1078-0432.CCR-21-4462. Clin Cancer Res. 2022. PMID: 35259259 Free PMC article. Clinical Trial.
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition.
Li BT, Daly B, Gospodarowicz M, Bertagnolli MM, Brawley OW, Chabner BA, Fashoyin-Aje L, de Claro RA, Franklin E, Mills J, Legos J, Kaucic K, Li M, The L, Hou T, Wu TH, Albrecht B, Shao Y, Finnegan J, Qian J, Shahidi J, Gasal E, Tendler C, Kim G, Yan J, Morrow PK, Fuchs CS, Zhang L, LaCaze R, Oelrich S, Murphy MJ, Pazdur R, Rudd K, Wu YL. Li BT, et al. Among authors: fashoyin aje l. Nat Med. 2022 Apr;28(4):620-626. doi: 10.1038/s41591-022-01775-6. Nat Med. 2022. PMID: 35440725 No abstract available.
52 results